Quansheng Feng
Overview
Explore the profile of Quansheng Feng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
165
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yan D, Qiao L, Huang W, Zhang X, Ma C, Feng Q, et al.
J Pharm Anal
. 2025 Mar;
15(2):101047.
PMID: 40034864
Image 1.
2.
Dan L, Li X, Chen S, You X, Wang D, Wang T, et al.
Front Pharmacol
. 2025 Feb;
16:1512184.
PMID: 39936090
Background: The pathological progression from liver injury to fibrosis is a hallmark of liver disease, with no effective strategies to halt this transition. Ginsenoside Rg1 has demonstrated a range of...
3.
Liu T, Li S, Wang X, Liu M, Wang Y, Ying J, et al.
Virol J
. 2025 Jan;
22(1):19.
PMID: 39875956
Infection with Influenza A virus (IAV) induces severe inflammatory responses and lung injury, contributing significantly to mortality and morbidity rates. Alterations in the microbial composition of the lungs and intestinal...
4.
Liu H, Sun X, Tao S, Liu S, Wang X, Chen Q, et al.
Front Pharmacol
. 2024 Oct;
15:1444439.
PMID: 39474608
Introduction: Due to the high mortality rate and increasing severity of antibiotic resistance, there is a growing interest in new treatments for ae (KP)-induced pneumonia. Research has shown that the...
5.
Xu X, Liu J, Li X, Feng Q, Su Y
Heliyon
. 2024 Sep;
10(16):e36267.
PMID: 39224343
Chronic hepatitis B infection (CHB) is a major risk factor for the development of hepatocellular carcinoma (HCC) globally and continues to pose a significant global health challenge. Jiawei Yinchenhao decoction...
6.
Li X, Zhou L, Xu X, Liu X, Wu W, Feng Q, et al.
Front Pharmacol
. 2024 Aug;
15:1392241.
PMID: 39086383
Background And Aims: Metabolic reprogramming has been found to be a typical feature of tumors. Hepatocellular carcinoma (HCC), a cancer with high morbidity and mortality, has been extensively studied for...
7.
Li X, Xu X, Tao S, Su Y, Wen L, Wang D, et al.
Front Pharmacol
. 2024 Apr;
15:1347120.
PMID: 38606180
The occurrence and development of Hepatic fibrosis (HF) are closely related to the gut microbial composition and alterations in host metabolism. Qijia Rougan decoction (QJ) is a traditional Chinese medicine...
8.
Chen Q, Sun Q, Zhang J, Li B, Feng Q, Liu J
PLoS One
. 2024 Mar;
19(3):e0295090.
PMID: 38437209
Background: To evaluate the cost-effectiveness of Tislelizumab vs Sorafenib as the first-line treatment of unresectable hepatocellular carcinoma (HCC) from the perspective of the Chinese health service system. Methods: A lifetime...
9.
Feng Y, Fu R, Sun H, Wang X, Yang Y, Wen C, et al.
Artif Intell Med
. 2024 Jan;
147:102744.
PMID: 38184351
Background And Objective: Recently, computational fluid dynamics enables the non-invasive calculation of fractional flow reserve (FFR) based on 3D coronary model, but it is time-consuming. Currently, machine learning technique has...
10.
Feng Y, Li B, Fu R, Hao Y, Wang T, Guo H, et al.
Comput Methods Programs Biomed
. 2023 Oct;
242:107862.
PMID: 37857024
Background And Objective: The functional assessment of the severity of coronary stenosis from coronary computed tomography angiography (CCTA)-derived fractional flow reserve (FFR) has recently attracted interest. However, existing algorithms run...